首页|血液透析并血液灌流治疗糖尿病肾病的疗效及对脂肪因子与炎症因子的影响

血液透析并血液灌流治疗糖尿病肾病的疗效及对脂肪因子与炎症因子的影响

扫码查看
目的 分析糖尿病肾病(DN)患者采用血液透析并血液灌流治疗的疗效及对脂肪因子与炎症因子的影响。方法 将2019年7月至2022年11月济源市人民医院收治的80例DN患者随机分为试验组和对照组,每组40例,分别给予血液透析并血液灌流治疗及血液透析联合血液透析滤过治疗。结果 试验组总有效率(67。50%)明显高于对照组(42。50%),两组临床疗效差异有统计学意义(P<0。05),试验组治疗后脂肪因子抵抗素、脂联素、瘦素改善较对照组明显,炎症因子[肿瘤坏死因子-α(TNF-α)、超敏C反应蛋白(hs-CRP)、白细胞介素-6(IL-6)]较对照组下降明显,两组治疗后脂肪因子与炎症因子差异有统计学意义(P<0。05)。结论 血液透析并血液灌流治疗可提高DN患者的临床疗效,有效改善脂肪因子与炎症因子。
Effect of hemodialysis and hemoperfusion on diabetic nephropathy and its influence on adipokines and inflammatory factors
[Objective]To analyze the effect of hemodialysis and hemoperfusion on adipokines and inflammatory factors in patients with diabetes nephropathy(DN).[Methods]Eighty patients with DN admitted to Jiyuan People's Hospital were randomly divided into an experimental group and a control group,with 40 cases in each group.They were treated with hemodialysis and hemoperfusion therapy,as well as hemodialysis combined with hemodialysis filtration therapy.[Results]The total effective rate of 67.50%in the experimental group was significantly higher than that of 42.50%in the control group,and there was a significant difference in clinical efficacy between the two groups(P<0.05).After treatment,the experimental group showed significant improvement in the levels of fat factor resistin,adiponectin,and leptin compared with the control group.Inflammatory factors such as tumor necrosis factor-α(TNF-α),high-sensitivity C-reactive protein(hs-CRP),and interleukin-6(IL-6)decreased significantly compared with the control group.After treatment,there was a significant difference in adipose factors and inflammatory factors between the two groups(P<0.05).[Conclusion]Hemodialysis combined with hemoperfusion therapy can improve the clinical efficacy of DN patients and effectively improve adipocytokines and inflammatory factors.

diabetes nephropathyhemodialysisblood perfusionclinical efficacyfatty factorsinflammatory factors

常小利

展开 >

济源市人民医院肾病内分泌科,河南济源 459000

糖尿病肾病 血液透析 血液灌流 临床疗效 脂肪因子 炎症因子

2024

中国医学工程
中国医药生物技术协会 卫生部肝胆肠外科研究中心

中国医学工程

影响因子:0.504
ISSN:1672-2019
年,卷(期):2024.32(8)